Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director · CEO and President | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verrica Pharmaceuticals Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,593 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-14 · Purchase · Acquired 20,000 · Balance 202,593 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 2 · 2026-08-17 · Purchase · Acquired 5,000 · Balance 207,593 |
| Common StockSEC Table I · non-derivative | IndirectBy child | 15 |
Reported balance
Holding disclosure · report date 2026-08-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 230 |
Reported balance
Holding disclosure · report date 2026-08-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 230 F2: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 230 |
Reported balance
Holding disclosure · report date 2026-08-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 230 F2: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 230 |
Reported balance
Holding disclosure · report date 2026-08-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 230 F2: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 5,000 | $4.91 | $24,550.00 |
DisclosureSEC source: 0002043558-26-000005 · form4-08182026_050802.xml · nonDerivative · entry 2 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,593 Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 20,000 | $5.06 | $101,200.00 |
DisclosureSEC source: 0002043558-26-000005 · form4-08182026_050802.xml · nonDerivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,593 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 512,269 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0002043558-26-000002 · form4-06092026_040610.xml · derivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,269 Underlying: Common Stock · 512,269 shares Expires 2035-12-23 F1 · date: The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026. F2 · derivative.exercise_date: 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 00:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries C Warrant (right to buy) · Derivative | 23,577 | Not disclosed Strike: $6.32 | Not disclosed |
DisclosureSEC source: 0002043558-25-000003 · form4-11252025_071107.xml · derivative · entry 6 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,577 Underlying: Common Stock · 23,577 shares Expires 2030-11-25 F4 · price: The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 00:00 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 94,311 | $4.24 | $400,114.42 |
DisclosureSEC source: 0002043558-25-000003 · form4-11252025_071107.xml · nonDerivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,593 F1 · balance_after: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 850,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-25-008506 · form4-03182025_060303.xml · derivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2035-03-14 F1 · derivative.exercise_date: 1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 26, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027711 · form4-11262024_041106.xml · nonDerivative · entry 2 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882,826 Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries B Warrants (right to buy) · Derivative | 140,449 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001415889-24-027711 · form4-11262024_041106.xml · derivative · entry 8 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,449 Underlying: Common Stock · 140,449 shares Expires 2029-11-22 F1 · price: The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries A Warrants (right to buy) · Derivative | 140,449 | Not disclosed Strike: $1.07 | Not disclosed |
DisclosureSEC source: 0001415889-24-027711 · form4-11262024_041106.xml · derivative · entry 7 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,449 Underlying: Common Stock · 140,449 shares Expires 2025-11-22 F1 · price: The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 280,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027711 · form4-11262024_041106.xml · nonDerivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,826 F1 · price: The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 02:02 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-026286 · form4-11072024_021140.xml · derivative · entry 1 Rieger Jayson · CIK 0002043558 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2034-11-06 F1 · derivative.exercise_date: 1/8th of the total shares subject to the option shall vest on May 5, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.